Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

Cited In for PubMed (Select 19348557)

1.

Optimal vaccination in a stochastic epidemic model of two non-interacting populations.

Yuan EC, Alderson DL, Stromberg S, Carlson JM.

PLoS One. 2015 Feb 17;10(2):e0115826. doi: 10.1371/journal.pone.0115826. eCollection 2015.

2.

African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.

Matsuoka Y, Suguitan A Jr, Orandle M, Paskel M, Boonnak K, Gardner DJ, Feldmann F, Feldmann H, Marino M, Jin H, Kemble G, Subbarao K.

J Virol. 2014 Jul;88(14):8139-52. doi: 10.1128/JVI.00425-14. Epub 2014 May 7.

3.

Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Isakova-Sivak I, Chen LM, Bourgeois M, Matsuoka Y, Voeten JT, Heldens JG, van den Bosch H, Klimov A, Rudenko L, Cox NJ, Donis RO.

Clin Vaccine Immunol. 2014 May;21(5):722-31. doi: 10.1128/CVI.00819-13. Epub 2014 Mar 19.

4.

Vaccine chronicle in Japan.

Nakayama T.

J Infect Chemother. 2013 Oct;19(5):787-98. doi: 10.1007/s10156-013-0641-6. Epub 2013 Jul 9. Review.

5.

Molecular basis of live-attenuated influenza virus.

He W, Wang W, Han H, Wang L, Zhang G, Gao B.

PLoS One. 2013;8(3):e60413. doi: 10.1371/journal.pone.0060413. Epub 2013 Mar 26.

6.

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model.

Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN.

PLoS One. 2011;6(8):e23791. doi: 10.1371/journal.pone.0023791. Epub 2011 Aug 18.

7.

Assessing the ecotoxicologic hazards of a pandemic influenza medical response.

Singer AC, Colizza V, Schmitt H, Andrews J, Balcan D, Huang WE, Keller VD, Vespignani A, Williams RJ.

Environ Health Perspect. 2011 Aug;119(8):1084-90. doi: 10.1289/ehp.1002757. Epub 2011 Mar 2.

8.

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M.

J Clin Immunol. 2011 Jun;31(3):443-54. doi: 10.1007/s10875-010-9490-6. Epub 2010 Dec 21.

9.

Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.

Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL.

PLoS One. 2010 Oct 4;5(10):e13162. doi: 10.1371/journal.pone.0013162.

10.

Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model.

David SA, Volokhov DV, Ye Z, Chizhikov V.

Appl Environ Microbiol. 2010 May;76(9):2718-28. doi: 10.1128/AEM.02776-09. Epub 2010 Mar 12.

11.

Combination strategies for pandemic influenza response - a systematic review of mathematical modeling studies.

Lee VJ, Lye DC, Wilder-Smith A.

BMC Med. 2009 Dec 10;7:76. doi: 10.1186/1741-7015-7-76. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk